Pancreatic Cancer Research

ResearcherKaohsiung Medical UniversityActive in the last 2 years

Li‐Tzong Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3250-7167; OpenAlex author ID A5102820625, A5112652793. Sources: OpenAlex.

Their work

Papers
58 (first author 5, last author 18)
Trials
0
Grants
0
Labs led
1
Collaborators
108
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 5 papers · 2017: 2 papers · 2018: 4 papers · 2019: 10 papers · 2020: 7 papers · 2021: 4 papers · 2022: 11 papers · 2023: 4 papers · 2024: 2 papers · 2025: 3 papers · 2026: 4 papers

Papers 50 of 58

  1. Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immunotherapy efficacy in ARID1A-… Co-author DOI 10.1007/s00262-026-04498-6↗
  2. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Last author DOI 10.1016/j.ejca.2026.116229↗
  3. Exploring the characteristics of the SKP2-CDK6 axis in pancreatic cancer cell metastasis and its clinical significance. Co-author DOI 10.1016/j.yexmp.2026.105024↗
  4. A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC. Co-author DOI 10.1158/1078-0432.ccr-25-4564↗
  5. Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition. Co-author DOI 10.1002/ctm2.70394↗
  6. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
  7. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  8. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  9. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan. Last author DOI 10.1186/s12929-024-01008-7↗
  10. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which P… Co-author DOI 10.1016/j.ijrobp.2023.02.061↗
  11. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Co-author DOI 10.1097/js9.0000000000000495↗
  12. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Last author DOI 10.3390/cancers15041008↗
  13. Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination. Last author PMID 37693128↗
  14. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  15. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - T… Last author DOI 10.1016/j.ejca.2022.06.043↗
  16. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative On… Last author DOI 10.1038/s41416-021-01649-7↗
  17. Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment. Co-author DOI 10.1186/s13046-022-02329-x↗
  18. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Last author DOI 10.3389/fonc.2022.800842↗
  19. The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy. First author DOI 10.3390/biomedicines10040926↗
  20. Semaphorin 6C Suppresses Proliferation of Pancreatic Cancer Cells via Inhibition of the AKT/GSK3/β-Catenin/Cyclin D1 Pathway. Last author DOI 10.3390/ijms23052608↗
  21. Clustering of Chromatin Remodeling Enzymes Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Pancreatic Cancer. Co-author DOI 10.7150/ijms.73800↗
  22. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  23. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Last author PMID 35693078↗
  24. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  25. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A … Co-author DOI 10.1016/j.pan.2020.10.029↗
  26. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: Fr… Co-author DOI 10.1016/j.radonc.2021.02.037↗
  27. No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol. First author DOI 10.1038/s41598-021-94111-w↗
  28. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  29. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Last author DOI 10.1016/j.ejca.2019.10.023↗
  30. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Last author DOI 10.1038/s41598-020-64421-6↗
  31. Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Last author DOI 10.1038/s41598-020-77250-4↗
  32. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… First author DOI 10.1097/mpa.0000000000001455↗
  33. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Last author DOI 10.1111/cas.14264↗
  34. Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan. First author DOI 10.1186/s12929-020-00664-9↗
  35. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-cente… Co-author DOI 10.1371/journal.pone.0244487↗
  36. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Co-author DOI 10.1016/j.ejca.2018.09.029↗
  37. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Last author DOI 10.1016/j.ejca.2018.12.007↗
  38. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. Co-author DOI 10.1016/j.jgo.2019.02.011↗
  39. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer. Co-author DOI 10.1186/s12943-019-1023-1↗
  40. Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer. Co-author DOI 10.1186/s13045-019-0769-7↗
  41. Deciphering The Potential Role of Hox Genes in Pancreatic Cancer. Co-author DOI 10.3390/cancers11050734↗
  42. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers11081068↗
  43. Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Co-author DOI 10.3390/jcm8060903↗
  44. β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer. Co-author DOI 10.7150/thno.28201↗
  45. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. Co-author DOI 10.7150/thno.36830↗
  46. The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation-wide cancer registry-based study from Taiwan. First author DOI 10.1002/cam4.1795↗
  47. Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development. Co-author DOI 10.1080/2162402x.2018.1424612↗
  48. Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression. Co-author DOI 10.3390/cancers11010008↗
  49. The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. Co-author DOI 10.4143/crt.2017.105↗
  50. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … Co-author DOI 10.1038/bjc.2017.67↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan‐Shen Shan · 35 shared papers, 2011–2026 · strength 4.77
  2. Nai‐Jung Chiang · 22 shared papers, 2016–2026 · strength 3.12
  3. Yung‐Yeh Su · 19 shared papers, 2020–2026 · strength 2.96
  4. Wen‐Chun Hung · 12 shared papers, 2016–2026 · strength 2.07
  5. Chung‐Pin Li · 14 shared papers, 2018–2026 · strength 1.92
  6. Jen‐Shi Chen · 14 shared papers, 2011–2026 · strength 1.84
  7. Li‐Yuan Bai · 11 shared papers, 2020–2026 · strength 1.62
  8. Wen‐Chi Chou · 10 shared papers, 2021–2025 · strength 1.41
  9. Tai‐Jan Chiu · 9 shared papers, 2019–2026 · strength 1.27
  10. Hui‐Jen Tsai · 8 shared papers, 2018–2026 · strength 1.10
  11. Shih‐Hung Yang · 8 shared papers, 2021–2024 · strength 1.07
  12. Yen‐Yang Chen · 8 shared papers, 2021–2024 · strength 1.07
  13. Ya‐Chin Hou · 5 shared papers, 2019–2026 · strength 1.01
  14. Ying‐Jui Chao · 7 shared papers, 2019–2026 · strength 0.99
  15. Tzu‐Lei Kuo · 4 shared papers, 2019–2026 · strength 0.98
  16. Cheng‐Ming Peng · 7 shared papers, 2021–2024 · strength 0.92
  17. Bruce Belanger · 8 shared papers, 2016–2021 · strength 0.78
  18. Mei‐Ren Pan · 6 shared papers, 2016–2026 · strength 0.78
  19. Jens Thomas Siveke · 8 shared papers, 2017–2021 · strength 0.77
  20. Yu‐Hsuan Hung · 4 shared papers, 2019–2023 · strength 0.73
  21. Jeffrey Shu-Ming Chang · 6 shared papers, 2016–2024 · strength 0.66
  22. Andrea Wang‐Gillam · 7 shared papers, 2016–2020 · strength 0.60
  23. Jean‐Frédéric Blanc · 6 shared papers, 2017–2021 · strength 0.59
  24. Floris A. de Jong · 6 shared papers, 2017–2021 · strength 0.59
  25. Hui‐Ching Wang · 3 shared papers, 2020–2026 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.